GlassScriptPhysician profile
Jeremy B Moad
NPI 1134325608
$4,243.67
in general payments reported to CMS, 2019-2025
28 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $152 · 2021: $455 · 2022: $704 · 2023: $478 · 2024: $970 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.62 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $552.02 | 2019-2025 | Tezspire, Breztri |
| Glaxosmithkline, LLC. | $363.91 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $285.84 | 2021-2025 | |
| Amgen INC. | $281.71 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $280.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $232.82 | 2022-2025 | Dupixent |
| Baxter Healthcare | $206.87 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $198.84 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Fisher & Paykel Healthcare INC | $163.78 | 2019-2023 | Fisher & Paykel Healthcare |
| Csl Behring | $125.74 | 2019-2022 | |
| Insmed, INC. | $112.05 | 2019-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $99.12 | 2021-2025 | Glassia |
| Sunovion Pharmaceuticals INC. | $98.47 | 2019 | |
| Pfizer INC. | $90.66 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.81 | 2019-2022 | |
| Harmony Biosciences LLC | $61.49 | 2023 | Wakix |
| Vifor Pharma, INC. | $54.09 | 2024-2025 | Zemaira |
| Merck Sharp & Dohme LLC | $49.37 | 2024-2025 | Capvaxive |
| Janssen Pharmaceuticals, INC | $39.34 | 2019 | |
| United Therapeutics Corporation | $31.14 | 2024 | Tyvaso |
| Electromed, INC. | $29.10 | 2025 | Smartvest |
| Mylan Specialty L.P. | $24.83 | 2019 | |
| Advanced Respiratory, INC | $24.13 | 2020 | |
| Viatris Specialty LLC | $19.77 | 2025 | Yupelri |
| Chiesi USA, INC. | $15.14 | 2021 | |
| Grifols USA, LLC | $12.84 | 2020 | |
| Circassia INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Moad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.